Table 1.

Patient characteristics and association between HPD and anatomoclinical categorical variables (univariate analysis)

All patients (n = 131)Non-HPD (n = 119)HPD (n = 12)P (Fisher exact test)
Gender0.14
 Male71 (54%)67 (56%)4 (33%)
 Female60 (46%)52 (44%)8 (67%)
RMH score0.43
 035 (27%)33 (28%)2 (17%)
 147 (36%)44 (37%)3 (25%)
 242 (32%)36 (30%)6 (50%)
 37 (5%)6 (5%)1 (8%)
Metastatic site0.76
 ≤258 (44%)52 (44%)6 (50%)
 >273 (56%)67 (56%)6 (50%)
Histology0.29
 Melanoma45 (34%)41 (91%)4 (9%)
 Lung13 (10%)13 (100%)0
 Renal9 (7%)9 (100%)0
 Colorectal8 (6%)7 (88%)1 (12%)
 Urothelial8 (6%)6 (75%)2 (25%)
 Lymphoma7 (5%)6 (86%)1 (14%)
 HCC6 (5%)6 (100%)0
 Head and neck6 (5%)6 (100%)0
 Ovarian5 (4%)3 (60%)2 (40%)
 Breast4 (3%)4 (100%)0
 Glioblastoma4 (3%)4 (100%)0
 Cervix2 (2%)2 (100%)0
 Cholangiocarcinoma2 (2%)1 (50%)1 (50%)
 Endometrium2 (2%)2 (100%)0
 Gastric, esophagus2 (2%)2 (100%)0
 Thyroid2 (2%)2 (100%)0
 Uveal melanoma2 (2%)1 (50%)1 (50%)
 Mesothelioma1 (1%)1 (100%)0
 Pancreas1 (1%)1 (100%)0
 Parotid1 (1%)1 (100%)0
 Sarcoma1 (1%)1 (100%)0
Type of ICB1
 PD-1 inhibitor78 (60%)71 (60%)7 (58%)
 PD-L1 inhibitor53 (40%)48 (40%)5 (42%)
PD-L1 status (IHC)0.24
 Positive32 (25%)30 (94%)2 (67%)
 Negative3 (2%)2 (6%)1 (33%)
Number of previous lines: median (range)2.0 (0–9)2.0 (0–9)2.5 (0–6)0.69
Corticosteroids at baseline0.16
 No123 (94%)113 (95%)10 (83%)
 Yes8 (6%)6 (5%)2 (17%)
Previous radiation therapy0.77
 No72 (55%)66 (55%)6 (50%)
 Yes59 (45%)53 (45%)6 (50%)
Previous chemotherapy0.75
 No43 (33%)40 (34%)3 (25%)
 Yes88 (67%)79 (66%)9 (75%)
Previous targeted therapy0.55
 No58 (44%)54 (45%)4 (33%)
 Yes73 (56%)65 (55%)8 (67%)
Previous immunotherapy0.39
 No111 (85%)102 (86%)9 (75%)
 Yes20 (15%)17 (14%)3 (25%)
  • Abbreviations: HCC, hepatocellular carcinoma; ICB, immune checkpoint blockade; IHC, immunohistochemistry.